TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10716466
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs. NA alone
Study: 9184390
Drug: Fixed minidose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed minidose warfarin 1.25 mg/day
Study: 9184390
Drug: Combined minidose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined minidose warfarin (1.25 mg/day) and aspirin (300 mg/day)
Study: 9184390
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose adjusted warfarin (INR 2.0-3.0)
Study: 3816922
Drug: Alinidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 40 mg p.o.
Study: 25639140
Drug: Animal-source food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-source food supplement 5 days per week from marriage to term (approximately 13 months)
Study: 25639140
Drug: Animal-source food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-source food supplement 5 days per week from 16 weeks of gestation to term (approximately 5 months)
Study: 18160963
Drug: Standard hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hepatitis B vaccine (double doses)
Study: 18160963
Drug: Booster doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster doses of HBV‐AS04
Study: 7723156
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention to promote adherence to a diet providing 28% of energy from total fat, less than 8% from saturated fat, up to 9% from polyunsaturated fat, and less than 75 mg/4200 kJ (1000 kcal) per day of cholesterol (not to exceed 150 mg/d)
Study: 31342138
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.2 g/d of elemental calcium in the form of calcium carbonate)
Study: 28779963
Drug: 36 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group)
Study: 28779963
Drug: Reduced-dose and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose and partial-breast radiotherapy
Study: 23033005
Drug: Capecitabine (cape)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (cape) treatment with HFSR
Study: 23033005
Drug: Capecitabine (cape)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (cape) treatment without HFSR
Study: 19796562
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E gel (D-alpha-tocopheryl acetate) applied twice a week
Study: 18079221
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg/d for 4 weeks)
Study: 10745058
Drug: Testosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (250 mg testosterone enanthate)
Study: 8942440
Drug: Early versus
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early versus deferred antiretroviral treatment
Study: 1561479
Drug: 200 UI/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 UI/day of salmon calcitonin (CT) by nasal spray
Study: 1561479
Drug: Placebo by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by nasal spray
Study: 27364372
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) group: initial arthrocentesis plus PRP injection and then four consecutive PRP injections.
Study: 27364372
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) group: one session of arthrocentesis plus HA injection.
Study: 20650471
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline 2.5 mg
Study: 20650471
Drug: 20% basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% basal rate insulin reduction for 6 hours
Study: 18757014
Drug: Drained serums
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drained serums prepared by an infusion system and a three-way valve
Study: 15914526
Drug: rhGH (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (6 mg SC daily)
Study: 12769161
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and low-dose diuretics
Study: 11379860
Drug: 1.1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% amino acid dialysis solution (AADS)
Study: 11379860
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis solutions (control)
Study: 15321377
Drug: SM: 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM: 0.1 mg
Study: 15321377
Drug: SM: 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM: 0.2 mg
Study: 15321377
Drug: SM: 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM: 0.1 mg plus K 60 mg i.v. one hour after spinal injection, and 30 mg i.v. every 6 h for three doses
Study: 26988231
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature stable carbetocin (100 μg intramuscular)
Study: 26988231
Drug: Oxytocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (10 IU intramuscular)
Study: 24359507
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/day with cognitive-behavior and motivation-enhancement therapy
Study: 24359507
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with cognitive-behavior and motivation-enhancement therapy
Study: 22480131
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (100-1600 mcg)
Study: 20574411
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal gel (0.05%)
Study: 20574411
Drug: Gel 4789
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel 4789 (Dapivirine vaginal gel)
Study: 20574411
Drug: Hydroxyethyl cellulose-based
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl cellulose-based universal placebo gel
Study: 15868442
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in patients with moderate cyclin D1 expression
Study: 8689817
Drug: R(+)‐terodiline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(+)‐terodiline hydrochloride (100 mg)
Study: 8689817
Drug: Racemic terodiline
Normalized name: terodiline
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic terodiline hydrochloride (200 mg)
Study: 8689817
Drug: S(‐)‐terodiline tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(‐)‐terodiline tartrate (100 mg)
Study: 27910185
Drug: Paclitaxel drug-eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-eluting balloon (DEB) angioplasty
Study: 24402636
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg/day of zinc gluconate for 8 weeks)
Study: 11923554
Drug: Intrapleural urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural urokinase 40,000 units in 40 ml, administered 12 hourly for 3 days
Study: 11923554
Drug: Saline (placebo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo), administered 12 hourly for 3 days
Study: 11923554
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of urokinase and small percutaneous drain
Study: 7658954
Drug: Progressive Resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Resistance Training (PRT) at 80% or more of 1RM, training twice weekly for 12 months.
Study: 1106447
Drug: oxazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxazepam (30 mg) and alcohol (0.75 g/kg) combined
Study: 1106447
Drug: alcohol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcohol (0.75 g/kg)
Study: 26036329
Drug: Topical 30%
Normalized name: urea topical 30% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 30% resin lacquer once daily for 9 months
Study: 26036329
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% amorolfine lacquer once weekly for 9 months
Study: 26036329
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg once daily for 3 months
Study: 26036329
Drug: Topical 30%
Normalized name: urea topical 30% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 30% resin lacquer
Study: 26036329
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% amorolfine lacquer
Study: 20084896
Drug: rBS/WC oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBS/WC oral cholera vaccine
Study: 16680923
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate DPI, 200 microg, once daily in the evening
Study: 15166553
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol and remifentanil
Study: 2663386
Drug: External shock-wave
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External shock-wave lithotripsy (ESL) and adjuvant ursodiol therapy
Study: 2663386
Drug: Ursodiol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol therapy alone
Study: 4574639
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks cyclophosphamide therapy
Study: 4574639
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks cyclophosphamide therapy
Study: 4574639
Drug: steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid treatment alone
Study: 25370206
Drug: 100-mg sildenafil
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg sildenafil
Study: 2249406
Drug: 1 mgF-
Normalized name: ALLANTOIN 0.5 in 25 g TOPICAL PATCH [Cellapy MGF Hydro Gel Intense Mask]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mgF- tablets plus fortnightly rinsing at school with 1000 ppmF-
Study: 2249406
Drug: 1 mgF-
Normalized name: ALLANTOIN 0.5 in 25 g TOPICAL PATCH [Cellapy MGF Hydro Gel Intense Mask]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mgF- tablets plus placebo rinsing
Study: 2249406
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets plus 1000 ppmF- rinsing
Study: 2249406
Drug: Active tablet/active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tablet/active rinse group
Study: 2249406
Drug: Active tablet/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tablet/placebo rinse group
Study: 2249406
Drug: Tablet-only children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-only children
Study: 30730346
Drug: Intradermal Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Botulinum Toxin (BTX) injections
Study: 23095307
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg/2 weeks
Study: 21172842
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) 20 mg/kg/day
Study: 17652181
Drug: Cinacalcet 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 50 mg orally once daily for 8 days
Study: 11896478
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg daily) and sildenafil (100 mg 1 h before sexual intercourse)
Study: 10213258
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (S)
Study: 3042876
Drug: WC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC vaccine
Study: 19064822
Drug: Half-dose TIV
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose TIV
Study: 19064822
Drug: Full-dose TIV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose TIV
Study: 16100237
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg kg(‐1) in isotonic saline 0.2 ml kg(‐1)
Study: 16100237
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg kg(‐1) in isotonic saline 0.2 ml kg(‐1)
Study: 9710008
Drug: Diuretic (trichlormethiazide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (trichlormethiazide, 2 mg daily)
Study: 9710008
Drug: NSAID-slow release
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-slow release (tenoxicam-SR, 20 mg daily)
Study: 9710008
Drug: Steroid (prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (prednisolone, 20 mg daily for 2 weeks, then 10 mg daily for 2 weeks)
Study: 2841905
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg/m2
Study: 2841905
Drug: Carboplatin 400
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 400 mg/m2
Study: 2841905
Drug: Carboplatin 450
Normalized name: CARBOPLATIN 450MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin 450 mg/m2
Study: 1244812
Drug: Calcium heparinate
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparinate (low doses, administered subcutaneously)
Study: 1244812
Drug: Sodium pentosan
Normalized name: Pentosan Polysulfate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium pentosan polysulfate (administered intramuscularly)
Study: 25146365
Drug: Amlodipine camsylate/losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate/losartan 5/100 mg/d (AML/LOS)
Study: 25146365
Drug: Losartan/hydrochlorothiazide 100/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/hydrochlorothiazide 100/12.5 mg/d (LOS/HCTZ)
Study: 20664127
Drug: Humor group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor group (self-selected humor for 30 minutes daily)
Study: 20664127
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard cardiac therapy)
Study: 15458908
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/d or 120 mg/d
Study: 11167350
Drug: Cetirizine (C)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (C) 10 mg daily for 2 weeks
Study: 24283773
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg per week for 12 weeks
Study: 21348912
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Study: 19056900
Drug: 20,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU cholecalciferol twice a week
Study: 19056900
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a week
Study: 1655299
Drug: edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 1 mg.kg‐1 (single-dose)
Study: 1655299
Drug: edrophonium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 0.75 mg.kg‐1 (single-dose)
Study: 1655299
Drug: edrophonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 0.25 mg.kg‐1 followed by 0.75 mg.kg‐1 (divided-dose)
Study: 1655299
Drug: edrophonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 0.25 mg.kg‐1 followed by 0.50 mg.kg‐1 (divided-dose)
Study: 1655299
Drug: edrophonium (divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium (divided doses)
Study: 6751003
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment (25 mg hydrochlorothiazide and 50 mg triamterene)
Study: 30711665
Drug: Directed training
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed training for Instrumental Activities of Daily Living (IADL) using web-based programs for driving and fraud avoidance
Study: 27911341
Drug: MAO-B inhibitors
Normalized name: MAO B Inhibitors, dopaminergic anti-parkinson drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAO-B inhibitors
Study: 21941012
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g of NaHCO3 per kilogram body mass)
Study: 21941012
Drug: Placebo (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.15 g of corn flour per kilogram body mass)
Study: 19685757
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection 0.6 mL x kg(‐1) added to physiological saline 250 mL after anaesthesia before CPB
Study: 19685757
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline 250 mL
Study: 8526620
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II heparin coat
Study: 8526620
Drug: Carmeda Biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carmeda Biological Active Surface
Study: 20535962
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine with high-dose IL-2
Study: 20535962
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell (DC) vaccine of prostate-acid protein plus GM-CSF
Study: 20535962
Drug: MAGE-A3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 vaccine for non-small cell lung cancer
Study: 12669250
Drug: Biochemotherapy (cisplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemotherapy (cisplatinum 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3 i.v., Interferon-alpha2b 10 MIU s.c. 3 days a week, on a 28-day cycle)
Study: 8979185
Drug: No umbilical
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No umbilical catheter; peripheral intravenous lines only (control group)
Study: 6427714
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms mestranol plus 0.5 mg ethynodiol diacetate (100 M + 0.5 ED)
Study: 6427714
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms mestranol plus 1.0 mg ethynodiol diacetate (100 M + 1.0 ED)
Study: 6427714
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms ethinyl estradiol plus 1.0 mg ethynodiol diacetate (50 EE + 1.0 ED)
Study: 6427714
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyl estradiol plus 2.0 mg ethynodiol diacetate (30 EE + 2.0 ED)
Study: 6427714
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyl estradiol plus 0.15 mg levonorgestrel (30 EE + 0.15 NG)
Study: 30998422
Drug: Erythromycin (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2% w/v) with zinc acetate (1.2% w/v) topical gel
Study: 30998422
Drug: Erythromycin (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2% w/v) gel alone
Study: 24411797
Drug: Drug positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug positive (marijuana and other drugs) among sober drivers
Study: 24411797
Drug: Drug positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug positive (marijuana and other drugs) among drinking drivers
Study: 24411797
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs (excluding marijuana)
Study: 15869543
Drug: Myobloc (botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myobloc (botulinum toxin type B) 2500 U (0.5 ml) per axilla
Study: 15869543
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml vehicle (placebo)
Study: 12672711
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (150 micro g of selenium, 2000 IU of retinol, 120 mg of ascorbic acid, 30 IU of alpha‐tocopherol) with taper training (TT)
Study: 12672711
Drug: Taper training
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper training (TT)
Study: 8808777
Drug: Combined dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined dipyridamole (150 mg) and aspirin (100 mg) pellet formulation
Study: 8808777
Drug: Conventional products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional products (dipyridamole and aspirin) given twice daily
Study: 2413307
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg i.v.) plus Naloxone (0.4 mg i.v.)
Study: 2413307
Drug: Naloxone (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4, 2.0, and 8.0 mg i.v.)
Study: 30452784
Drug: Fulacimstat 5
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulacimstat 5 mg twice daily (n=9)